Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122860085> ?p ?o ?g. }
- W2122860085 endingPage "582.e1" @default.
- W2122860085 startingPage "574" @default.
- W2122860085 abstract "Background & AimsObeticholic acid (OCA; INT-747, 6α-ethyl-chenodeoxycholic acid) is a semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, the natural agonist of the farnesoid X receptor, which is a nuclear hormone receptor that regulates glucose and lipid metabolism. In animal models, OCA decreases insulin resistance and hepatic steatosis.MethodsWe performed a double-blind, placebo-controlled, proof-of-concept study to evaluate the effects of OCA on insulin sensitivity in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus. Patients were randomly assigned to groups given placebo (n = 23), 25 mg OCA (n = 20), or 50 mg OCA (n = 21) once daily for 6 weeks. A 2-stage hyperinsulinemic-euglycemic insulin clamp was used to measure insulin sensitivity before and after the 6-week treatment period. We also measured levels of liver enzymes, lipid analytes, fibroblast growth factor 19, 7α-hydroxy-4-cholesten-3-one (a BA precursor), endogenous bile acids, and markers of liver fibrosis.ResultsWhen patients were given a low-dose insulin infusion, insulin sensitivity increased by 28.0% from baseline in the group treated with 25 mg OCA (P = .019) and 20.1% from baseline in the group treated with 50 mg OCA (P = .060). Insulin sensitivity increased by 24.5% (P = .011) in combined OCA groups, whereas it decreased by 5.5% in the placebo group. A similar pattern was observed in patients given a high-dose insulin infusion. The OCA groups had significant reductions in levels of γ-glutamyltransferase and alanine aminotransferase and dose-related weight loss. They also had increased serum levels of low-density lipoprotein cholesterol and fibroblast growth factor 19, associated with decreased levels of 7α-hydroxy-4-cholesten-3-one and endogenous bile acids, indicating activation of farnesoid X receptor. Markers of liver fibrosis decreased significantly in the group treated with 25 mg OCA. Adverse experiences were similar among groups.ConclusionsIn this phase 2 trial, administration of 25 or 50 mg OCA for 6 weeks was well tolerated, increased insulin sensitivity, and reduced markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Longer and larger studies are warranted. ClinicalTrials.gov, Number: NCT00501592. Obeticholic acid (OCA; INT-747, 6α-ethyl-chenodeoxycholic acid) is a semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, the natural agonist of the farnesoid X receptor, which is a nuclear hormone receptor that regulates glucose and lipid metabolism. In animal models, OCA decreases insulin resistance and hepatic steatosis. We performed a double-blind, placebo-controlled, proof-of-concept study to evaluate the effects of OCA on insulin sensitivity in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus. Patients were randomly assigned to groups given placebo (n = 23), 25 mg OCA (n = 20), or 50 mg OCA (n = 21) once daily for 6 weeks. A 2-stage hyperinsulinemic-euglycemic insulin clamp was used to measure insulin sensitivity before and after the 6-week treatment period. We also measured levels of liver enzymes, lipid analytes, fibroblast growth factor 19, 7α-hydroxy-4-cholesten-3-one (a BA precursor), endogenous bile acids, and markers of liver fibrosis. When patients were given a low-dose insulin infusion, insulin sensitivity increased by 28.0% from baseline in the group treated with 25 mg OCA (P = .019) and 20.1% from baseline in the group treated with 50 mg OCA (P = .060). Insulin sensitivity increased by 24.5% (P = .011) in combined OCA groups, whereas it decreased by 5.5% in the placebo group. A similar pattern was observed in patients given a high-dose insulin infusion. The OCA groups had significant reductions in levels of γ-glutamyltransferase and alanine aminotransferase and dose-related weight loss. They also had increased serum levels of low-density lipoprotein cholesterol and fibroblast growth factor 19, associated with decreased levels of 7α-hydroxy-4-cholesten-3-one and endogenous bile acids, indicating activation of farnesoid X receptor. Markers of liver fibrosis decreased significantly in the group treated with 25 mg OCA. Adverse experiences were similar among groups. In this phase 2 trial, administration of 25 or 50 mg OCA for 6 weeks was well tolerated, increased insulin sensitivity, and reduced markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Longer and larger studies are warranted. ClinicalTrials.gov, Number: NCT00501592." @default.
- W2122860085 created "2016-06-24" @default.
- W2122860085 creator A5014966457 @default.
- W2122860085 creator A5045462483 @default.
- W2122860085 creator A5049036517 @default.
- W2122860085 creator A5054183066 @default.
- W2122860085 creator A5058458204 @default.
- W2122860085 creator A5062630000 @default.
- W2122860085 creator A5068230851 @default.
- W2122860085 creator A5070639714 @default.
- W2122860085 creator A5074995506 @default.
- W2122860085 creator A5077201362 @default.
- W2122860085 creator A5078832883 @default.
- W2122860085 creator A5084625858 @default.
- W2122860085 creator A5089649262 @default.
- W2122860085 date "2013-09-01" @default.
- W2122860085 modified "2023-10-17" @default.
- W2122860085 title "Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease" @default.
- W2122860085 cites W1884764810 @default.
- W2122860085 cites W1966566190 @default.
- W2122860085 cites W1970740746 @default.
- W2122860085 cites W1971309492 @default.
- W2122860085 cites W1975673963 @default.
- W2122860085 cites W1978070564 @default.
- W2122860085 cites W1986688127 @default.
- W2122860085 cites W1990724339 @default.
- W2122860085 cites W2003541563 @default.
- W2122860085 cites W2003716266 @default.
- W2122860085 cites W2003905949 @default.
- W2122860085 cites W2021998283 @default.
- W2122860085 cites W2025873966 @default.
- W2122860085 cites W2028536174 @default.
- W2122860085 cites W2028825823 @default.
- W2122860085 cites W2032704998 @default.
- W2122860085 cites W2033083064 @default.
- W2122860085 cites W2037467390 @default.
- W2122860085 cites W2040086341 @default.
- W2122860085 cites W2041297399 @default.
- W2122860085 cites W2041451676 @default.
- W2122860085 cites W2044136233 @default.
- W2122860085 cites W2045223517 @default.
- W2122860085 cites W2049515100 @default.
- W2122860085 cites W2052064885 @default.
- W2122860085 cites W2060847352 @default.
- W2122860085 cites W2069505390 @default.
- W2122860085 cites W2075553194 @default.
- W2122860085 cites W2078519195 @default.
- W2122860085 cites W2078810890 @default.
- W2122860085 cites W2082752454 @default.
- W2122860085 cites W2092960198 @default.
- W2122860085 cites W2097677758 @default.
- W2122860085 cites W2105866876 @default.
- W2122860085 cites W2106678312 @default.
- W2122860085 cites W2113684928 @default.
- W2122860085 cites W2119560584 @default.
- W2122860085 cites W2122709204 @default.
- W2122860085 cites W2125632718 @default.
- W2122860085 cites W2129415792 @default.
- W2122860085 cites W2131101159 @default.
- W2122860085 cites W2131372305 @default.
- W2122860085 cites W2134059673 @default.
- W2122860085 cites W2134897177 @default.
- W2122860085 cites W2139112405 @default.
- W2122860085 cites W2139611479 @default.
- W2122860085 cites W2142427646 @default.
- W2122860085 cites W2158609797 @default.
- W2122860085 cites W2159639597 @default.
- W2122860085 cites W2162888435 @default.
- W2122860085 cites W2164418602 @default.
- W2122860085 cites W2167596859 @default.
- W2122860085 doi "https://doi.org/10.1053/j.gastro.2013.05.042" @default.
- W2122860085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23727264" @default.
- W2122860085 hasPublicationYear "2013" @default.
- W2122860085 type Work @default.
- W2122860085 sameAs 2122860085 @default.
- W2122860085 citedByCount "761" @default.
- W2122860085 countsByYear W21228600852013 @default.
- W2122860085 countsByYear W21228600852014 @default.
- W2122860085 countsByYear W21228600852015 @default.
- W2122860085 countsByYear W21228600852016 @default.
- W2122860085 countsByYear W21228600852017 @default.
- W2122860085 countsByYear W21228600852018 @default.
- W2122860085 countsByYear W21228600852019 @default.
- W2122860085 countsByYear W21228600852020 @default.
- W2122860085 countsByYear W21228600852021 @default.
- W2122860085 countsByYear W21228600852022 @default.
- W2122860085 countsByYear W21228600852023 @default.
- W2122860085 crossrefType "journal-article" @default.
- W2122860085 hasAuthorship W2122860085A5014966457 @default.
- W2122860085 hasAuthorship W2122860085A5045462483 @default.
- W2122860085 hasAuthorship W2122860085A5049036517 @default.
- W2122860085 hasAuthorship W2122860085A5054183066 @default.
- W2122860085 hasAuthorship W2122860085A5058458204 @default.
- W2122860085 hasAuthorship W2122860085A5062630000 @default.
- W2122860085 hasAuthorship W2122860085A5068230851 @default.
- W2122860085 hasAuthorship W2122860085A5070639714 @default.
- W2122860085 hasAuthorship W2122860085A5074995506 @default.
- W2122860085 hasAuthorship W2122860085A5077201362 @default.